fullerene c60 has been researched along with Apoplexy in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Ageev, SV; Jakovleva, AA; Kirik, OV; Kolpakova, ME; Korzhevskii, DE; Kukaliia, ON; Maistrenko, DN; Meshcheriakov, AA; Molchanov, OE; Murin, IV; Novikova, TA; Petrov, AV; Poliakova, LS; Semenov, KN; Sharoyko, VV; Vlasov, TD | 1 |
Cam, E; Fluri, F; Grünstein, D; Hatz, F; Israel, I; Kleinschnitz, C; Moch, H; Orts-Gil, G; Samnick, S; Schaeren-Wiemers, N; Schäfer, J; Seeberger, P; Ungethuem, U; Zeis, T | 1 |
2 other study(ies) available for fullerene c60 and Apoplexy
Article | Year |
---|---|
C
Topics: Antioxidants; Arginine; Fullerenes; Humans; Ischemia; Ischemic Stroke; Nanostructures; Stroke; Water | 2023 |
Fullerenols and glucosamine fullerenes reduce infarct volume and cerebral inflammation after ischemic stroke in normotensive and hypertensive rats.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Fullerenes; Glucosamine; Hypertension; Injections, Intravenous; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke | 2015 |